Type 1 Diabetes (T1D) is an autoimmune disease that remains underrecognized, especially in adults. The American Diabetes Association now recommends autoantibody screening for T1D, helping drive awareness of earlier identification and accurate diagnosis to prevent serious complications. Listen to our latest Healthier World episode to learn more: http://spr.ly/60497gOYB
The ADA shift toward routine autoantibody screening is a significant step because delayed Type 1 diagnosis is often a logistics problem, not a clinical one. Screening only drives earlier intervention if ordering is simple, turnaround is predictable, and results include clear guidance on what to do next. One question that keeps coming up across care teams: where are you seeing the biggest operational gap today, inconsistent ordering workflows, turnaround time, or uncertainty about how to manage presymptomatic patients once autoantibodies are identified?